ponatinib,blinatumomab
takeda,incyte,otsuka,amgen
['leusm', 'cml', 'leukemia', 'ponatinib', 'blinatumomab', 'ph+ all']
#eha23 encouraging results of blinatumomab/ponatinib from cr/cri rates: 92% in r/r ph+ all 86% in cml-lbp favorable safety profile #allsm #leusm #leukemia #endcancer 
Assistant Professor, 
Leukemia Department                                                                 
MD Anderson Cancer Center, Houston